Celgene MMV Partnership
Active Since: 2012
Contributing to SDGs…
Identifying new therapies to treat blood and liver-stage malaria.
Product development partnerships
Medicines for Malaria Venture (MMV)
- This project aims to identify new therapies to treat blood and liver-stage malaria.
What are the health needs and challenges?
The worldwide disease burden for malaria is enormous, with more than half of the world at risk and with the development of resistance to existing therapies.
Partnership activities and how they address needs and challenges
In collaboration with Medicines for Malaria Venture (MMV), Celgene has developed numerous new classes of anti-malarial treatments from a screening against the major pathogen, Plasmodium falciparum. Currently, the work is focused on identifying a single treatment that could be tested against various strains of malaria.
SDGs THE PARTNERSHIP CONTRIBUTES TO
SDG 3: Good Health and Wellbeing
- 3.3: Communicable Diseases & NTDs
SDG 9: Industry Innovation and Infrastructure
SDG 17: Partnerships for the Goals
Infectious and Parasitic Disease